Close Menu

OGT

The company believes cytogeneticists will adopt its panel to get high-quality SNV and CNV data in a single assay.

The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business. 

The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.

The revenue growth comes amid increased demand for the company's molecular genetics products.

Interviews with leading UK scientists revealed apprehension about losing access to European funding, limitations on freedom of movement, and an exodus of biotechs to the EU.

The kit detects the three most common aneuploidies associated with bladder cancer, as well as deletions of the 9p21.3 locus.

Sengenics is rebranding the technology Immunome and expects it to expand the company's footprint in the proteomics space.

The genomic products and services firm said that no assets or personnel will be transferred, but it will license its analysis software to Source BioScience.

The company plans to launch a suite of small cancer panels initially for research, but it could eventually seek regulatory approval for them as diagnostics. 

The arrays feature the addition of newly identified genomic regions, as well as the removal of ones found to have no pathogenic significance.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.